Can Journavx (suzetrigine) be added to a postoperative regimen that includes acetaminophen and PRN oxycodone, and what are the appropriate dosing, safety precautions, and contraindications?

Can Journavx (Suzetrigine) Be Added to Postoperative Acetaminophen and PRN Oxycodone?

Yes, Journavx (suzetrigine) can and should be added to a postoperative regimen with acetaminophen and PRN oxycodone as part of a multimodal, opioid-sparing analgesic strategy for moderate-to-severe acute pain in adults.

Dosing Regimen

Standard Dosing (Normal Hepatic Function)

• Dose 1 (Loading): 100 mg orally on empty stomach (at least 1 hour before or 2 hours after food). Clear liquids permitted (water, apple juice, vegetable broth, tea, black coffee) 1
• Doses 2-4: 50 mg orally every 12 hours starting 12 hours after initial dose (may take with or without food) 1
• Dose 5 and beyond: 50 mg orally every 24 hours starting 12 hours after Dose 4 (may take with or without food) 1
• Maximum duration: 14 days 1

Modified Dosing for Moderate Hepatic Impairment (Child-Pugh Class B)

• Dose 1: 100 mg orally on empty stomach 1
• Doses 2-4: 50 mg every 12 hours 1
• Dose 5 and beyond: 50 mg every 24 hours 1

Missed Dose Management

• If one dose missed: Take as soon as possible, then resume normal schedule 1
• If two or more doses missed: Take 100 mg, then resume normal schedule 1
• For patients with hepatic impairment or on moderate CYP3A inhibitors: If next dose within 6 hours, skip it and resume subsequent doses 1

Integration with Multimodal Analgesia

Journavx fits seamlessly into evidence-based multimodal postoperative pain protocols. Current guidelines strongly recommend scheduled acetaminophen and NSAIDs with rescue opioids for postoperative pain 2, 3, 4. Journavx adds a novel peripheral mechanism (selective NaV1.8 inhibition) that complements rather than duplicates these existing agents 5, 6.

Recommended Multimodal Regimen

• Scheduled: Acetaminophen 1 g every 8 hours 4
• Scheduled: Journavx per dosing above 1
• PRN rescue: Oxycodone (limit to lowest effective dose, shortest duration) 2, 3
• Consider adding: NSAIDs if not contraindicated 3, 7

Clinical evidence supports this approach: In a phase 4 study, 76.1% of patients receiving suzetrigine as part of multimodal therapy (with acetaminophen and ibuprofen) required no opioid rescue after arthroscopic or laparoscopic procedures 5. This is substantially better than the <50% opioid-free rate seen in similar surgeries without suzetrigine 5.

Safety Precautions and Monitoring

Critical Drug Interactions

Absolute Contraindication - Strong CYP3A Inhibitors

• Do NOT use Journavx with: ketoconazole, itraconazole, clarithromycin, ritonavir, or other strong CYP3A inhibitors 1
• Mechanism: Dramatically increases suzetrigine and active metabolite (M6-SUZ) exposure, causing adverse reactions 1

Dose Reduction Required - Moderate CYP3A Inhibitors

• Examples: erythromycin, diltiazem, verapamil, fluconazole, grapefruit products 1
• Use modified dosing regimen (same as hepatic impairment dosing above) 1
• Avoid all grapefruit-containing foods/drinks during treatment 1

Avoid Concomitant Use - CYP3A Inducers

• Examples: rifampin, carbamazepine, phenytoin, St. John's wort 1
• Mechanism: Reduces suzetrigine efficacy by decreasing drug exposure 1

Journavx as CYP3A Inducer - Affects Other Medications

Suzetrigine induces CYP3A, potentially reducing efficacy of CYP3A substrates 1. This is particularly important for:

Hormonal Contraceptives

• Patients on progestins OTHER than levonorgestrel or norethindrone must use additional non-hormonal contraception (condoms) or switch to alternative contraceptives during treatment and for 28 days after discontinuing Journavx 1
• Levonorgestrel/norethindrone-containing contraceptives are NOT affected 1

Other CYP3A Substrates

• Sensitive CYP3A substrates (e.g., certain immunosuppressants, anticoagulants, chemotherapy agents) may require dose adjustment 1
• Consult prescribing information for concomitant CYP3A substrates when initiating or discontinuing Journavx 1

Hepatic Impairment Considerations

• Mild hepatic impairment (Child-Pugh A): Standard dosing 1
• Moderate hepatic impairment (Child-Pugh B): Reduced dosing required (see above) due to higher drug exposure 1
• Severe hepatic impairment (Child-Pugh C): AVOID USE - insufficient safety data 1

Renal Impairment

• Dose adjustment required for renal impairment, though specific guidance not detailed in provided evidence 8

Contraindications

1. Concomitant use with strong CYP3A inhibitors 1
2. Severe hepatic impairment (Child-Pugh Class C) 1

Common Pitfalls to Avoid

Timing and Food Interactions

• First dose MUST be on empty stomach - this is critical for proper absorption 1
• Subsequent doses (2-4, then 5+) may be taken with food 1
• Missing this detail reduces initial analgesic effect

Duration Limits

• Maximum 14 days - Journavx is approved only for acute pain, not chronic use 1
• If pain persists beyond 14 days, reassess underlying cause

Opioid Expectations

• Journavx demonstrated non-inferiority (not superiority) to hydrocodone/acetaminophen in phase 3 trials 6
• Set realistic expectations: similar pain relief to opioids but without addiction risk, respiratory depression, or sedation 6, 9
• Onset to 2-point pain reduction: approximately 2-4 hours after abdominoplasty, 4 hours after bunionectomy 6

Combination Product Confusion

• Discontinue acetaminophen/opioid combination products (e.g., Percocet, Vicodin) when using scheduled acetaminophen to avoid acetaminophen overdose 4
• Use single-entity oxycodone for rescue if needed

Adverse Events Profile

Journavx was generally safe and well-tolerated in clinical trials 1, 6. Adverse events were:

• Mild to moderate in severity 6
• Consistent with postoperative settings 1
• Discontinuation rate due to adverse events: 0.6% (vs. 0% for placebo in trials) 1

No evidence of addiction, abuse, or physical dependence in animal or human studies to date 9. This represents a major safety advantage over opioids.

Clinical Positioning

Journavx represents a mechanistically novel addition to multimodal analgesia, targeting peripheral NaV1.8 sodium channels that are upregulated during inflammation and tissue injury 10, 11. This peripheral mechanism avoids central nervous system effects (sedation, respiratory depression, addiction) associated with opioids 10, 9.

The drug is particularly valuable when:

• Opioid minimization is a priority
• Patient has opioid-related risk factors (history of substance use disorder, respiratory compromise)
• NSAIDs are contraindicated (renal dysfunction, bleeding risk, cardiovascular disease) 4
• Moderate-to-severe acute pain is expected (e.g., abdominoplasty, bunionectomy, orthopedic procedures) 5, 6

Guideline alignment: Current enhanced recovery and postoperative pain guidelines emphasize scheduled non-opioid analgesics with opioid rescue 2, 3, 7, 12. Journavx fits this paradigm as a scheduled, non-opioid agent that enables opioid-sparing or opioid-free recovery 5.